Gene Therapy Market Share, Size, Trends, Industry Analysis Report, By Vector Type (Viral, Non-viral); By Approach (Gene Augmentation, Oncolytic Viral Therapy, Immunotherapy, Others); By Therapeutic Area; By Route of Administration; By Regions; Segment For

Gene Therapy Market Share, Size, Trends, Industry Analysis Report, By Vector Type (Viral, Non-viral); By Approach (Gene Augmentation, Oncolytic Viral Therapy, Immunotherapy, Others); By Therapeutic Area; By Route of Administration; By Regions; Segment Forecast, 2024 - 2032

The global gene therapy market expected to reach USD 43.13 billion by 2032, according to a new study by Polaris Market Research. The report “Gene Therapy Market Share, Size, Trends, Industry Analysis Report, By Vector Type (Viral, Non-viral); By Approach (Gene Augmentation, Oncolytic Viral Therapy, Immunotherapy, Others); By Therapeutic Area; By Route of Administration; By Regions; Segment Forecast, 2021 - 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The rising prevalence of chronic disorders including heredity and oncology diseases, rise in the number of clinical trials in the concerned arena, and increase in product approvals from regulatory agencies are few factors boosting the market growth. Moreover, innovations in the gene delivery systems also expedited the demand for such products.

The market is fragmented based on the therapy area, vector type, approach, route of administration, and region. In terms of therapeutic area, the market is segmented into autoimmune disorders, cardiovascular diseases, dermatological disorders, genetic disorders, hematological disorders, metabolic disorders, muscle-related diseases, oncological disorders, ophthalmic diseases, and others.

Based on the vector type, the industry is further bifurcated into viral and non-viral vectors. Based on the approach, the industry is further bifurcated into gene augmentation, oncolytic viral therapy, immunotherapy, and others. Based on the route of administration, the market is further bifurcated into intraarticular, intracerebellar, intradermal, intramuscular, intratumoral, intravenous, intravesical, intravitreal, subretinal, and others.

Segment Highlights

- The genetic disorders segment accounted for the largest revenue share in 2020 owing to the emergence of novel disorders and associated research and innovation. Furthermore, the increasing number of genetic disorders is expected to drive segment growth.

- Based on the vector type, the viral segment accounted for over 55% in terms of revenue in 2020. This can be attributed to its high accuracy in gene delivery and the presence of several players across the market.

- North America region is dominating the global market, holding almost one-third of the market share throughout the forecast period. Positive funding scenario and the presence of competent regulatory authorities favoring the growth in the region

- The players including Novartis AG, Celgene Corporation, and Gilead Sciences Inc. together account for a significant market share of the global market in the year 2020

List of Key Players

- Dimension Therapeutics

- Novartis AG

- Bluebird Bio

- Gilead Sciences Inc.

- Human Stem Cell Institute

- Spark Therapeutics

- Celgene Corporation

- Sangamo Biosciences

- GlaxoSmithKline

- Bristol Myer’s Squibb

- Celgene Corporation

- Others

Polaris Market Research has segmented the gene therapy market report on the basis of therapeutic area, vector type, approach, route of administration, and region

Gene Therapy, Therapeutic Area Outlook (Revenue - USD Million, 2016 - 2028)

- Autoimmune Disorders

- Cardiovascular Diseases

- Dermatological Disorders

- Genetic Disorders

- Hematological Disorders

- Metabolic Disorders

- Muscle-related Diseases

- Oncological Disorders

- Ophthalmic Diseases

- Others

Gene Therapy, Vector Type Outlook (Revenue - USD Million, 2016 - 2028)

- Viral

Retroviral vectors

- Gamma-retroviral vectors

- Lentiviral vectors

Adeno-associated virus vectors

other viral vectors

- Non-viral

Oligonucleotides

Other non-viral vectors

Gene Therapy, Approach Outlook (Revenue - USD Million, 2016 - 2028)

- Augmentation

- Oncolytic Viral Therapy

- Immunotherapy

- Others

Gene Therapy, Route of Administration Outlook (Revenue - USD Million, 2016 - 2028)

- Intraarticular

- Intracerebellar

- Intradermal

- Intramuscular

- Intratumoral

- Intravenous

- Intravesical

- Intravitreal

- Subretinal

- Others

Gene Therapy, Regional Outlook (Revenue - USD Million, 2016 - 2028)

- North America

U.S.

Canada

- Europe

France

Germany

UK

Italy

Spain

Netherlands

Austria

- Asia Pacific

China

India

Japan

Malaysia

South Korea

Indonesia

- Central & South America

Mexico

Brazil

Argentina

- Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa